Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Morning Den! Time to shake off the weekend & get down to business.
Happy Friday Den! Make the most of it, and I wish you all a great day and an even better weekend.
Access Initiates Phase I/II testing of Thiarabine
http://www.tradingmarkets.com/news/stock-alert/accp_access-initiates-phase-i/ii-blood-cancer-trial-1091279.html
Aug 05, 2010 (Datamonitor via COMTEX) --
Access Pharmaceuticals, a biopharmaceutical company, has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analogue for patients with hematologic malignancies.
The primary objective of the study is to determine the maximum tolerated dose in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose, the company reported.
The clinical development program follows previously conducted Phase I and Phase II trials of Thiarabine in solid tumors, where myelosuppression, particularly lymphopenia was dose limiting.
David Nowotnik, senior vice president of R&D at Access, said: "The findings in preclinical and clinical studies to this point have given us a strong indicator that Thiarabine could be highly beneficial in treating patients with hematologic malignancies. The new Phase I/II trial at MD Anderson, a cancer center, is the next step in our comprehensive plan to build on the strong set of data and clinical results that have been generated to date on Thiarabine."
1) Who Is Peter?
2) The number of my shares is irrelevant, weather that number be 1, 1000, 0r 10,000,000. I shouldn't have to apologize for doing my due diligence & research about the good things VMCI will offer in the future.
3) If you have nothing good to say, why say anything? Spend your time doing positive things and improving your own situation, instead of preaching evil.
Cheers.
Good Morning Den. Have a Tremendous Thursday!
Thanks for the info. Should be an exciting next few weeks.
Great News!
Morning Den. How Ya Feelin?
iMedicor was briefly mentioned as a strong element, combined with DMS, to get MuGard in the hands of as many people as possible.
May I also suggest listening to the replay of the CC to get as much accurate info as possible. Thanks, I hope that helps.
Positive Energy!
Details from the conference call yielded some good, wholesome, positive information.
Early results from tests show that 42% of patients treated with MuGard were spared from Any sign of mucositis.
This is a big deal because over 90% of all chemotherapy patients contract some form of mucositis.
anyone interested can check out the replay all week by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 269 and conference ID number 354692.
The CC was overall very positive.
Early results from tests show that 42% of patients treated with MuGard were spared from Any sign of mucositis.
This is a big deal because over 90% of all chemotherapy patients contract some form of mucositis.
anyone interested can check out the replay all week by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 269 and conference ID number 354692.
ACCP to hold conference call Today 8/3
to provide an update on the Company's strategy and activities surrounding the official launch its lead product, MuGard in North America. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Hoping for some GREAT News!
Access Pharmaceuticals to host conference call Today 8/3
to provide an update on the Company's strategy and activities surrounding the official launch its lead product, MuGard in North America. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Get Your Popcorn Ready!
With the release & increased distribution of MuGard through iMedicor's Clear Lobby, we should all see a boost.
Access Pharmaceuticals Signs Exclusive Specialty Distribution Agreement With BioScrip
http://www.prnewswire.com/news-releases/access-pharmaceuticals-signs-exclusive-specialty-distribution-agreement-with-bioscrip-98821654.html
Agreement Provides Multi-level Distribution Of Lead Product, Including Inventory In Over 30 Top Metro Areas
DALLAS and NEW YORK, July 20 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip (Nasdaq: BIOS) for its lead product, MuGard -- an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.
The agreement aligns the Company with comprehensive access to BioScrip's nationwide distribution platform and the ability to leverage the company's extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
BioScrip, Inc.
(www.bioscrip.com) (Nasdaq: BIOS) is a national provider of specialty pharmacy and home care products and services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivery of cost-effective access to prescription medications.
Its services are designed to improve clinical outcomes for chronic and acute healthcare conditions while controlling overall healthcare costs.
"As one of the largest, top-tier players in this space, BioScrip is well-established, reputable and focused on tailoring its programs to best fit and meet product manufacturers, provider and payers and patients' pharmacy service needs," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc.
He continued, "In addition to the varied services that they will provide us, this partnership also results in multiple delivery options for patients in need of MuGard, including overnight delivery, home delivery and live retail pharmacy sites in the top metropolitan areas. We believe offering various methods of receiving MuGard can significantly increase patient compliance and ultimately provide an important additional weapon to help improve the treatment outcome."
"BioScrip is proud to have been selected by Access to be its exclusive distribution and service partner for MuGard. Our vast clinical, sales and operational specialty pharmacy assets, combined with our deep oncology experience, put us in an unique position to provide services to the patient, manufacturer, provider and payor communities," said Scott Friedman, Senior VP of Trade Relations and Business Development for BioScrip, Inc.
"Signing a strong specialty distribution partner is a critical milestone for a successful entrance into the US market," said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc. He continued, "With its significant resources, deep capabilities and strong commitment to cancer patients, BioScrip is an ideal partner to have in place as we continue executing on our global-commercialization strategy for MuGard."
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
If all goes to plan in the next few weeks, it should be at 20 cents or better. Go VMCI GO!!!
Hope Everyone had a Great Weekend!
Good Morning Den! Hope you all enjoyed your weekend
What makes the difference between gargle/rinse and swallow is that when the MuGard travels down the throat and esophagus, it gives the throat a protective coating to prevent legions/sores associated with chemotherapy. Gargling then spitting out the rinse does not protect the throat as well as actually swallowing the rinse. There are also no reported side effects whatsoever from ingesting MuGard
I hope that helps. I'm a new investor in Access, have been reading up on both the pros/cons and feel that Access will be successful within the next 3-6 months once all the pieces are in place.
iMedicor announces the launch of Access Pharmas' MuGard product through its pharma online marketing portal, ClearLobby, and its direct sales channel, Direct Medical Solutions.
According to officials, the initial phase of the marketing program includes a targeted MuGard sampling program to select iMedicor users and the DMS' physician network. As previously announced, iMedicor has been selected by Access Pharmaceuticals, to support the North American commercial launch efforts of its lead product, MuGard - an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, a side effect of radiotherapy and/or chemotherapy.
MuGard is now being introduced to Centers of Excellence, Key Opinion Leaders, cancer research centers and selected physicians in the United States. The initial release of MuGard samples is part of a joint project that includes participation from iMedicor's user base and DMS, a network of direct field representatives with relationships to physicians and their practices. The full national launch is expected during the third quarter using iMedicor's Physician Communication System (PCS), and iMedicor's strategic partnership with Direct Medical Solutions (DMS) and other strategic partners.
"After many months of planning, we look forward to assisting Access Pharma with its introduction of MuGard on a national level," said Fred Zolla, CEO of iMedicor. He continued, "MuGard represents a potential blockbuster product that could significantly improve the quality of life for patients undergoing certain cancer treatments. iMedicor's ability to deliver essential information from a trusted source to specific physician audiences will significantly increase Access Pharma's marketing ROI."
"Our collective efforts have led to the positive acceptance of the first phase sampling program throughout the DMS network," commented Marian Bartosiewicz, CEO of DMS. She continued, "We are pleased to be part of the introduction of a product like MuGard that can offer measurable relief to patients undergoing radiation and chemotherapy."
"Teaming up with iMedicor and DMS is an important strategic step in launching MuGard in North America as it provides us the ability to introduce MuGard more rapidly and cost-effectively than we would expect through traditional distribution channels to doctors," said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc. He continued, "Along with this initial and on-going sample program, Access will be able to utilize the medical education aspects of the iMedicor system to further inform doctors about oral mucositis and MuGard, and to accelerate commercial uptake in the U.S. market."
iMedicor is a HIPAA-compliant, internet based communication solution for interoperable health information transfer.
Access Pharmaceuticals is a biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients.
DMS provides a shopping network of "Best of Breed" ancillary, medical and operational strategies to compliment healthcare businesses.
http://www.tradingmarkets.com/news/stock-alert/accp_imedicor-launches-access-pharmaceuticals-mugard-product-1077345.html
Thanks! We like it too. Hope to have our album finished by early 2011, it feels like we've been working on it forever.
I won't be going to Cabo (Lucky) but will be playing a few shows with my reggae band Dub Proof this weekend in NJ. Always Fun
iMedicor Launches Access Pharmaceuticals' MuGard through Clear Lobby Today.
http://www.tradingmarkets.com/news/stock-alert/accp_imedicor-launches-access-pharmaceuticals-mugard-product-1077345.html
iMedicor Launches Access Pharmaceuticals' MuGard Product through Clear Lobby
http://www.tradingmarkets.com/news/stock-alert/accp_imedicor-launches-access-pharmaceuticals-mugard-product-1077345.html
Happy Friday Den. Lets Get After It!
Hey Robot! Thats funny. A friend of mine was on vacation in upstate NY and saw a flyer in a music club that read "Looking to start a Reggae band, call ROBOT xxx-xxx-xxxx" Lol
Congrats Mel!
Hope you are all feeling good this morning. Positivity is the Key
Access planning full commercial availability by mid-August
http://biomedreports.com/articles/most-popular/45414-access-planning-full-commercial-availability-by-mid-august.html
Thanks for the warm welcome Connie!
Yes, I'm a n00b to this whole place, but people seem pretty cool around here, so please be patient with me as I work my way around here. Thank You ALL so very much!
Tremendous! Best wishes Connie.
3rd party OutsideIn Research proclaims Big gains for VMCI
http://www.outsideinresearch.com/vemics-inc-otcbb-vmciob-dba-im/2010/7/27/vemics-inc-otc-bb-vmciob-dba-imedicor.html
Real NEWS Alert! 3rd Party Research on VEMICS Inc.
http://www.outsideinresearch.com/vemics-inc-otcbb-vmciob-dba-im/
Enjoy.
Double Digits = Everyone WINS!
Amazing breakthrough for cancer patients in The USA!
Read the Release Here
MuGard, a FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, is now being introduced to Centers of Excellence, Key Opinion Leaders, cancer research centers and selected physicians in the United States.
Access Pharmaceuticals, Inc. (OTC Bulletin Board:ACCP.ob - News), a biopharmaceutical company specializing in products for cancer and supportive care, today announced its e-marketing partner, iMedicor (OTC Bulletin Board:VMCI.ob - News) commenced the initial phase of a multi-channel marketing program for MuGard.
Amazing breakthrough for cancer patients in The USA!
insert-text-here
MuGard, a FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis and stomatitis, is now being introduced to Centers of Excellence, Key Opinion Leaders, cancer research centers and selected physicians in the United States.
Access Pharmaceuticals, Inc. (OTC Bulletin Board:ACCP.ob - News), a biopharmaceutical company specializing in products for cancer and supportive care, today announced its e-marketing partner, iMedicor (OTC Bulletin Board:VMCI.ob - News) commenced the initial phase of a multi-channel marketing program for MuGard.
Agreed. I'm new here too and could use the info. Thank You All.
My father is is need of something like this... this is great news....this revenue will really vmci also!
this is fantastic!